Form 4: Pacira BioSciences Director Christopher Christie Receives Significant Equity Compensation

Pacira BioSciences, Inc. Director Christopher Christie reported the acquisition of 6,163 restricted stock units and 11,279 stock options on June 11, 2025, as part of his compensation.

Summary

• Director Christopher Christie of Pacira BioSciences, Inc. (PCRX) acquired 6,163 shares of common stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 and represent the contingent right to receive one share of common stock each, vesting on June 11, 2026, subject to continuous service with the issuer.
• Following this transaction, Mr. Christie beneficially owns 16,654 shares of common stock.
• Additionally, Mr. Christie acquired 11,279 stock options with an exercise price of $24.34 on June 11, 2025.
• These stock options vest and become exercisable on June 11, 2026, contingent on continuous service, and have an expiration date of June 11, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: The filing reports a standard equity compensation grant to a director, which is generally a positive sign of aligning interests and retaining talent. There are no negative financial implications or red flags, indicating a neutral to slightly positive sentiment.

Positives

• The grant of restricted stock units and stock options to Director Christopher Christie aligns his interests with long-term shareholder value, as vesting is contingent on continuous service.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged, compliant transaction, reducing concerns about opportunistic insider trading.

Risks

• The vesting of both restricted stock units and stock options is contingent upon the reporting person remaining in continuous service with Pacira BioSciences, Inc. through June 11, 2026. If service ceases, these awards may be forfeited.

Future Outlook

The grants of restricted stock units and stock options are forward-looking, with vesting scheduled for June 11, 2026, contingent on the director's continued service, indicating an expectation of ongoing commitment and contribution from the director.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across the biotechnology and pharmaceutical industries to incentivize long-term commitment and align executive interests with shareholder returns. Such grants are standard components of director compensation packages, particularly in growth-oriented sectors like biotech where long-term value creation is paramount.

Comparison to Industry Standards

• The equity compensation structure, involving both restricted stock units (RSUs) and stock options with a vesting period, is a common and widely accepted practice in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar equity-based incentives for their directors and executives to foster long-term alignment.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide comparative data.
• The exercise price of $24.34 for the options would be the market price on the grant date, which is standard practice for stock option grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: No direct impact on general employees, but reflects the company's compensation strategy for key personnel.

Next Steps

• Continued service of Christopher Christie with Pacira BioSciences, Inc. through June 11, 2026, for the vesting of RSUs and stock options.
• Potential exercise of stock options by Christopher Christie between June 11, 2026, and June 11, 2035.

Key Dates

Keywords

Pacira BioSciences, PCRX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Rule 10b5-1, Corporate Governance